Compare POWW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWW | LCTX |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 255.4M |
| IPO Year | 2018 | 1996 |
| Metric | POWW | LCTX |
|---|---|---|
| Price | $2.22 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.40 | ★ $6.25 |
| AVG Volume (30 Days) | 435.5K | ★ 978.6K |
| Earning Date | 02-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.61 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $14.56 | $109.40 |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | $108.75 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $1.39 | $1.00 |
| 52 Week High | $2.67 | $2.09 |
| Indicator | POWW | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 40.52 |
| Support Level | $1.96 | N/A |
| Resistance Level | $2.46 | $1.18 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 92.59 | 12.50 |
Outdoor Holding Co the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketplace segment consists of the GunBroker e-commerce marketplace. The company generates the majority of its revenue from the Ammunition segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.